Sarepta Therapeutics, Inc.
SRPTHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic. The company carries a $2.38B market cap, placing it firmly in the mid-cap category. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Market Cap
$2.38B
Beta
0.26
P/E (TTM)
—
P/E (Fwd)
8.76
EPS (TTM)
$-1.57
EPS (Fwd)
$2.57
ROE
-9.5%
ROA
-1.1%
Cash
$788.5M
Total Debt
$1.06B
Free CF
$22.1M
52W Change
27.6%
Annual Financials
Cash vs Debt
Where SRPT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SRPT finished 25.60% above its 150-day moving average ($18.48) and 21.33% above its 200-day moving average ($19.13). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SRPT overbought or oversold?
At the September 3, 2026 close, SRPT's RSI(14) was 73.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Sarepta Therapeutics, Inc. carries $1.06B in total debt against $788.5M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $22.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -9.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $933.0M (2022) to $2.20B (2025), reflecting a 136% increase over the period.
SRPT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SRPT.